Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 11/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 11/20 | 0.62 |
| ▸ | HDAC11 | Q96DB2 | 10/20 | 0.62 |
| ▸ | HDAC3 | O15379 | 11/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 11/20 | 0.57 |
| ▸ | HDAC4 | P56524 | 11/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 10/20 | 0.57 |
| ▸ | HDAC7 | Q8WUI4 | 9/20 | 0.57 |
| ▸ | HDAC10 | Q969S8 | 9/20 | 0.57 |
| ▸ | HDAC9 | Q9UKV0 | 9/20 | 0.57 |
| ▸ | HDAC5 | Q9UQL6 | 9/20 | 0.57 |
| ▸ | RELA | Q04206 | 4/20 | 0.52 |
| ▸ | MEF2D | Q14814 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1320084 | 1.00 | HDAC8 (0.62) | HDAC8HDAC6HDAC11HDAC3HDAC1 | |
| SCHEMBL1320011 | 0.89 | HDAC4 (0.72) | HDAC8HDAC6HDAC11HDAC3HDAC1 | |
| SCHEMBL1320344 | 0.89 | HDAC4 (0.72) | HDAC8HDAC6HDAC11HDAC3HDAC1 | |
| SCHEMBL1320345 | 0.89 | HDAC4 (0.72) | HDAC8HDAC6HDAC11HDAC3HDAC1 | |
| SCHEMBL1320010 | 0.89 | HDAC4 (0.72) | HDAC8HDAC6HDAC11HDAC3HDAC1 | |
| SCHEMBL1321421 | 0.88 | HDAC1 (0.61) | HDAC8HDAC6HDAC11HDAC3HDAC1 | |
| SCHEMBL1321066 | 0.88 | HDAC1 (0.55) | HDAC8HDAC6HDAC11HDAC3HDAC1 | |
| SCHEMBL1321420 | 0.88 | HDAC1 (0.61) | HDAC8HDAC6HDAC11HDAC3HDAC1 | |
| SCHEMBL1321067 | 0.88 | HDAC1 (0.55) | HDAC8HDAC6HDAC11HDAC3HDAC1 | |
| SCHEMBL1321341 | 0.88 | HDAC8 (0.60) | HDAC8HDAC6HDAC11HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1814850-B9 | NEW HISTONE DEACETYLASES INHIBITORS | DAC SRL (IT) | 2015-02-25 | — | — | EP | claimed |
| EP-1814850-B1 | NEW HISTONE DEACETYLASES INHIBITORS | DAC SRL (IT) | 2013-07-03 | — | — | EP | claimed |
| US-8058273-B2 | Histone deacetylases inhibitors | DAC S.R.L. (IT) | 2011-11-15 | — | — | US | claimed |
| US-7803800-B2 | Histone deacetylases inhibitors | DAC S.R.L. (IT) | 2010-09-28 | — | — | US | claimed |
| US-20100240660-A1 | NEW HISTONE DEACETYLASES INHIBITORS | DAC S.R.L. (IT) | 2010-09-23 | — | — | US | claimed |
| US-20080096889-A1 | Histone Deacetylases Inhibitors | GENEXTRA S.P.A. (IT) | 2008-04-24 | — | — | US | claimed |
| EP-1814850-B9 | NEW HISTONE DEACETYLASES INHIBITORS | DAC SRL (IT) | 2015-02-25 | — | — | EP | disclosed |
| EP-1814850-B1 | NEW HISTONE DEACETYLASES INHIBITORS | DAC SRL (IT) | 2013-07-03 | — | — | EP | disclosed |
| US-8058273-B2 | Histone deacetylases inhibitors | DAC S.R.L. (IT) | 2011-11-15 | — | — | US | disclosed |
| US-8058273-B2 | Histone deacetylases inhibitors | DAC S.R.L. (IT) | 2011-11-15 | — | — | US | disclosed |
| US-8058273-B2 | Histone deacetylases inhibitors | DAC S.R.L. (IT) | 2011-11-15 | — | — | US | disclosed |
| US-7803800-B2 | Histone deacetylases inhibitors | DAC S.R.L. (IT) | 2010-09-28 | — | — | US | disclosed |
| US-7803800-B2 | Histone deacetylases inhibitors | DAC S.R.L. (IT) | 2010-09-28 | — | — | US | disclosed |
| US-7803800-B2 | Histone deacetylases inhibitors | DAC S.R.L. (IT) | 2010-09-28 | — | — | US | disclosed |
| US-20100240660-A1 | NEW HISTONE DEACETYLASES INHIBITORS | DAC S.R.L. (IT) | 2010-09-23 | — | — | US | disclosed |
| US-20100240660-A1 | NEW HISTONE DEACETYLASES INHIBITORS | DAC S.R.L. (IT) | 2010-09-23 | — | — | US | disclosed |
| US-20100240660-A1 | NEW HISTONE DEACETYLASES INHIBITORS | DAC S.R.L. (IT) | 2010-09-23 | — | — | US | disclosed |
| US-20080096889-A1 | Histone Deacetylases Inhibitors | GENEXTRA S.P.A. (IT) | 2008-04-24 | — | — | US | disclosed |
| US-20080096889-A1 | Histone Deacetylases Inhibitors | GENEXTRA S.P.A. (IT) | 2008-04-24 | — | — | US | disclosed |
| US-20080096889-A1 | Histone Deacetylases Inhibitors | GENEXTRA S.P.A. (IT) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240660-A1 | NEW HISTONE DEACETYLASES INHIBITORS | HDAC1, HDAC3, HDAC11 | HDAC8 9/4885HDAC6 10/4885HDAC11 3/4885 |
| US-20080096889-A1 | Histone Deacetylases Inhibitors | HDAC1, HDAC3, HDAC11 | HDAC8 9/4885HDAC6 11/4885HDAC11 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.